Skip to main content
Top
Published in: BMC Cancer 1/2012

Open Access 01-12-2012 | Study protocol

Rationale and design of a multicenter prospective cohort study for the eVALuation and monitoring of HPV infections and relATEd cervical diseases in high-risk women (VALHIDATE study)

Authors: Giovanna Orlando, Elisabetta Tanzi, Liliane Chatenoud, Maria Gramegna, Giuliano Rizzardini, VALHIDATE Study Group

Published in: BMC Cancer | Issue 1/2012

Login to get access

Abstract

Background

Pap screening, an effective method for cervical cancer prevention, is now supported by molecular human papillomavirus (HPV) testing. Recently commercialised preventive vaccines also provide new tools for the primary prevention of cervical cancer. To determine appropriate prevention strategies, the Health General Direction, Lombardy Region, funded a project that aims to characterize and monitor HPV infections and related cervical diseases in high-risk women.

Methods/design

VALHIDATE is a 5-year multicentre open prospective cohort study. It will recruit 7000 consenting women aged 13–65 years to provide information about the local biomolecular epidemiology of HPV infection and cervical diseases in high-risk women recruited from nine clinical centres and one faith-based organisation. The study will estimate the overall and type-specific prevalence of HPV infection and cervical abnormalities. It also aims to compare standard Pap screening with biomolecular screening, and to assist in the design of targeted regional prevention programs directed specifically at high-risk groups. Three groups of high-risk women: 1000 HIV-infected women (aged 26–65 years), 1000 recent migrant women (aged 26–65 years) and 3000 young women (aged 13–26 years) and 1 control group: 2000 women (aged 26–45 years) attending a spontaneous screening program, will be recruited. Sample sizes will be revised after the first year. Adult participants will undergo conventional cervical cytology, HPV DNA screening and genotyping. Paediatric participants will undergo HPV DNA testing and genotyping of urine samples. HPV DNA, cytological abnormalities and HPV types will be analysed according to demographic, epidemiological, behavioural, and clinical data collected in an electronic case report form. Overall and stratified prevalences will be estimated to analyse the associations between HPV infection and selected characteristics. Logistic regression models will be used to estimate crude and adjusted odds ratios. Cox proportional hazard models will be used to estimate hazard ratios over time and between groups.

Discussion/main expected results

This study will provide substantial insight into HPV infections and related cervical diseases in high-risk groups and will help determine appropriate regional cervical cancer prevention strategies.
Appendix
Available only for authorised users
Literature
1.
go back to reference Runowicz CD: Molecular screening for cervical cancer—time to give up Pap tests?. New Engl J Med. 2007, 357: 1650-1653.CrossRefPubMed Runowicz CD: Molecular screening for cervical cancer—time to give up Pap tests?. New Engl J Med. 2007, 357: 1650-1653.CrossRefPubMed
2.
go back to reference Arbyn M, Raifu AO, Weiderpass E, Bray F, Anttila A: Trends of cervical cancer mortality in the member states of the European Union. Eur J Cancer. 2009, 45: 2640-2648.CrossRefPubMed Arbyn M, Raifu AO, Weiderpass E, Bray F, Anttila A: Trends of cervical cancer mortality in the member states of the European Union. Eur J Cancer. 2009, 45: 2640-2648.CrossRefPubMed
4.
go back to reference Clifford GM, Rana RK, Franceschi S, Smith JS, Gough NG, Pimenta JM: Human Papillomavirus Genotype Distribution in Low-Grade Cervical Lesions: Comparison by Geographic Region and with Cervical Cancer. Cancer Epidemiol Biomarkers Prev. 2005, 14: 1157-1164.CrossRefPubMed Clifford GM, Rana RK, Franceschi S, Smith JS, Gough NG, Pimenta JM: Human Papillomavirus Genotype Distribution in Low-Grade Cervical Lesions: Comparison by Geographic Region and with Cervical Cancer. Cancer Epidemiol Biomarkers Prev. 2005, 14: 1157-1164.CrossRefPubMed
5.
go back to reference Kitchener HC, Castle PE, Cox JT: Chapter 7: achievements and limitations of cervical cytology screening. Vaccine. 2006, 24 (Suppl 3): 63-70.CrossRef Kitchener HC, Castle PE, Cox JT: Chapter 7: achievements and limitations of cervical cytology screening. Vaccine. 2006, 24 (Suppl 3): 63-70.CrossRef
6.
go back to reference Bray F, Loos AH, McCarron P, Weiderpass E, Arbyn M, Moller H, Hakama M, Parkin DM: Trends in cervical squamous cell carcinoma incidence in 13 European countries: changing risk and the effects of screening. Cancer Epidemiol Biomarkers Prev. 2005, 14: 677-686.CrossRefPubMed Bray F, Loos AH, McCarron P, Weiderpass E, Arbyn M, Moller H, Hakama M, Parkin DM: Trends in cervical squamous cell carcinoma incidence in 13 European countries: changing risk and the effects of screening. Cancer Epidemiol Biomarkers Prev. 2005, 14: 677-686.CrossRefPubMed
7.
go back to reference Karim-Kos HE, de Vries E, Soerjomataram I, Lemmens V, Siesling S, Coebergh JW: Recent trends of cancer in Europe: a combined approach of incidence, survival and mortality for 17 cancer sites since the 1990s. Eur J Cancer. 2008, 44: 1345-1389.CrossRefPubMed Karim-Kos HE, de Vries E, Soerjomataram I, Lemmens V, Siesling S, Coebergh JW: Recent trends of cancer in Europe: a combined approach of incidence, survival and mortality for 17 cancer sites since the 1990s. Eur J Cancer. 2008, 44: 1345-1389.CrossRefPubMed
8.
go back to reference de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, Tous S, Felix A, Bravo LE, Shin HR, Vallejos CS, de Ruiz PA, Lima MA, Guimera N, Clavero O, Alejo M, Llombart-Bosch A, Cheng-Yang C, Tatti SA, Kasamatsu E, Iljazovic E, Odida M, Prado R, Seoud M, Grce M, Usubutun A, Jain A, Suarez GA, Lombardi LE, Banjo A, Retrospective International Survey and HPV Time Trends Study Group: Human papillomavirus genotype attribution in invasive cervical cancer, et al: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010, 11: 1048-1056.CrossRefPubMed de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, Tous S, Felix A, Bravo LE, Shin HR, Vallejos CS, de Ruiz PA, Lima MA, Guimera N, Clavero O, Alejo M, Llombart-Bosch A, Cheng-Yang C, Tatti SA, Kasamatsu E, Iljazovic E, Odida M, Prado R, Seoud M, Grce M, Usubutun A, Jain A, Suarez GA, Lombardi LE, Banjo A, Retrospective International Survey and HPV Time Trends Study Group: Human papillomavirus genotype attribution in invasive cervical cancer, et al: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010, 11: 1048-1056.CrossRefPubMed
9.
go back to reference Ronco G, Giorgi-Rossi P, Carozzi F, Confortini M, Dalla Palma P, Del Mistro A, Ghiringhello B, Girlando S, Gillio-Tos A, De Marco L, Naldoni C, Pierotti P, Rizzolo R, Schincaglia P, Zorzi M, Zappa M, Segnan N, Cuzick J, New Technologies for Cervical Cancer screening (NTCC) Working Group: Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomized controlled trial. Lancet Oncol. 2010, 11: 249-257.CrossRefPubMed Ronco G, Giorgi-Rossi P, Carozzi F, Confortini M, Dalla Palma P, Del Mistro A, Ghiringhello B, Girlando S, Gillio-Tos A, De Marco L, Naldoni C, Pierotti P, Rizzolo R, Schincaglia P, Zorzi M, Zappa M, Segnan N, Cuzick J, New Technologies for Cervical Cancer screening (NTCC) Working Group: Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomized controlled trial. Lancet Oncol. 2010, 11: 249-257.CrossRefPubMed
10.
go back to reference Leinonen M, Nieminen P, Kotaniemi-Talonen L, Malila N, Tarkkanen J, Laurila P, Anttila A: Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting. J Natl Cancer Inst. 2009, 101: 1612-1623.CrossRefPubMed Leinonen M, Nieminen P, Kotaniemi-Talonen L, Malila N, Tarkkanen J, Laurila P, Anttila A: Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting. J Natl Cancer Inst. 2009, 101: 1612-1623.CrossRefPubMed
11.
go back to reference Mayrand MH, Duarte-Franco E, Rodrigues I, Walter SD, Hanley J, Ferenczy A, Ratnam S, Coutlée F, Franco EL, Canadian Cervical Cancer Screening Trial Study Group: Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med. 2007, 357: 1579-1588.CrossRefPubMed Mayrand MH, Duarte-Franco E, Rodrigues I, Walter SD, Hanley J, Ferenczy A, Ratnam S, Coutlée F, Franco EL, Canadian Cervical Cancer Screening Trial Study Group: Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med. 2007, 357: 1579-1588.CrossRefPubMed
12.
go back to reference Naucler P, Ryd W, Törnberg S, Strand A, Wadell G, Elfgren K, Rådberg T, Strander B, Forslund O, Hansson BG, Hagmar B, Johansson B, Rylander E, Dillner J: Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening. J Natl Cancer Inst. 2009, 101: 88-99.CrossRefPubMed Naucler P, Ryd W, Törnberg S, Strand A, Wadell G, Elfgren K, Rådberg T, Strander B, Forslund O, Hansson BG, Hagmar B, Johansson B, Rylander E, Dillner J: Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening. J Natl Cancer Inst. 2009, 101: 88-99.CrossRefPubMed
13.
go back to reference Sankaranarayanan R, Nene BM, Shastri SS, Jayant K, Muwonge R, Budukh AM, Hingmire S, Malvi SG, Thorat R, Kothari A, Chinoy R, Kelkar R, Kane S, Desai S, Keskar VR, Rajeshwarkar R, Panse N, Dinshaw KA: HPV screening for cervical cancer in rural India. N Engl J Med. 2009, 360: 1385-1394.CrossRefPubMed Sankaranarayanan R, Nene BM, Shastri SS, Jayant K, Muwonge R, Budukh AM, Hingmire S, Malvi SG, Thorat R, Kothari A, Chinoy R, Kelkar R, Kane S, Desai S, Keskar VR, Rajeshwarkar R, Panse N, Dinshaw KA: HPV screening for cervical cancer in rural India. N Engl J Med. 2009, 360: 1385-1394.CrossRefPubMed
14.
go back to reference de Kok IM, van Rosmalen J, Dillner J, Arbyn M, Sasieni P, Iftner T, van Ballegooijen M: Primary screening for human papillomavirus compared with cytology screening for cervical cancer in European settings: cost effectiveness analysis based on a Dutch microsimulation model. BMJ. 2012, 344: e670-10.1136/bmj.e670.CrossRefPubMedPubMedCentral de Kok IM, van Rosmalen J, Dillner J, Arbyn M, Sasieni P, Iftner T, van Ballegooijen M: Primary screening for human papillomavirus compared with cytology screening for cervical cancer in European settings: cost effectiveness analysis based on a Dutch microsimulation model. BMJ. 2012, 344: e670-10.1136/bmj.e670.CrossRefPubMedPubMedCentral
15.
go back to reference Khan MJ, Castle PE, Lorincz AT, Wacholder S, Sherman M, Scott DR, Rush BB, Glass AG, Schiffman M: The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst. 2005, 97: 1072-1079.CrossRefPubMed Khan MJ, Castle PE, Lorincz AT, Wacholder S, Sherman M, Scott DR, Rush BB, Glass AG, Schiffman M: The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst. 2005, 97: 1072-1079.CrossRefPubMed
16.
go back to reference Kjaer SK, Frederiksen K, Munk C, Iftner T: Longterm absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence. J Natl Cancer Inst. 2010, 102: 1478-1488.CrossRefPubMedPubMedCentral Kjaer SK, Frederiksen K, Munk C, Iftner T: Longterm absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence. J Natl Cancer Inst. 2010, 102: 1478-1488.CrossRefPubMedPubMedCentral
17.
go back to reference Dillner J, Rebolj M, Birembaut P, Petry KU, Szarewski A, Munk C, de Sanjose S, Naucler P, Lloveras B, Kjaer S, Cuzick J, van Ballegooijen M, Clavel C, Iftner T, Joint European Cohort Study: Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ. 2008, 337: a1754-CrossRefPubMedPubMedCentral Dillner J, Rebolj M, Birembaut P, Petry KU, Szarewski A, Munk C, de Sanjose S, Naucler P, Lloveras B, Kjaer S, Cuzick J, van Ballegooijen M, Clavel C, Iftner T, Joint European Cohort Study: Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ. 2008, 337: a1754-CrossRefPubMedPubMedCentral
18.
go back to reference Barzon L, Giorgi C, Buonaguro FM, Palù G, Italian Society for Virology: Guidelines of the Italian Society for Virology on HPV testing and vaccination for cervical cancer prevention. Infect Agent Cancer. 2008, 3: 14-CrossRefPubMedPubMedCentral Barzon L, Giorgi C, Buonaguro FM, Palù G, Italian Society for Virology: Guidelines of the Italian Society for Virology on HPV testing and vaccination for cervical cancer prevention. Infect Agent Cancer. 2008, 3: 14-CrossRefPubMedPubMedCentral
19.
go back to reference Wright TC, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D, 2006 American Society for Colposcopy and Cervical Pathology-sponsored Consensus Conference: 2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests. Am J Obstet Gynecol. 2007, 197: 346-355.CrossRefPubMed Wright TC, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D, 2006 American Society for Colposcopy and Cervical Pathology-sponsored Consensus Conference: 2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests. Am J Obstet Gynecol. 2007, 197: 346-355.CrossRefPubMed
20.
go back to reference Arbyn M, Anttila A, Jordan J, Ronco G, Schenck U, Segnan N, Wiener H, Herbert A, Von Karsa L: European guidelines for quality assurance in cervical cancer screening. Second edition–summary document. Ann Oncol. 2010, 21: 448-458.CrossRefPubMedPubMedCentral Arbyn M, Anttila A, Jordan J, Ronco G, Schenck U, Segnan N, Wiener H, Herbert A, Von Karsa L: European guidelines for quality assurance in cervical cancer screening. Second edition–summary document. Ann Oncol. 2010, 21: 448-458.CrossRefPubMedPubMedCentral
21.
go back to reference Muñoz N, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, Perez G, Brown DR, Koutsky LA, Tay EH, Garcia PJ, Ault KA, Garland SM, Leodolter S, Olsson SE, Tang GW, Ferris DG, Paavonen J, Steben M, Bosch FX, Dillner J, Huh WK, Joura EA, Kurman RJ, Majewski S, Myers ER, Villa LL, Taddeo FJ, Roberts C, Tadesse A, et al: Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J Natl Cancer Inst. 2010, 102: 325-339.CrossRefPubMed Muñoz N, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, Perez G, Brown DR, Koutsky LA, Tay EH, Garcia PJ, Ault KA, Garland SM, Leodolter S, Olsson SE, Tang GW, Ferris DG, Paavonen J, Steben M, Bosch FX, Dillner J, Huh WK, Joura EA, Kurman RJ, Majewski S, Myers ER, Villa LL, Taddeo FJ, Roberts C, Tadesse A, et al: Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J Natl Cancer Inst. 2010, 102: 325-339.CrossRefPubMed
22.
go back to reference Garland SM, Smith JS: Human papillomavirus vaccines: current status and future prospects. Drugs. 2010, 70: 1079-1098.CrossRefPubMed Garland SM, Smith JS: Human papillomavirus vaccines: current status and future prospects. Drugs. 2010, 70: 1079-1098.CrossRefPubMed
23.
go back to reference Schwarz T: Clinical update of the AS04-Adjuvanted human Papillomavirus-16/18 cervical cancer vaccine, Cervarix. Adv Ther. 2009, 26: 983-998.CrossRefPubMed Schwarz T: Clinical update of the AS04-Adjuvanted human Papillomavirus-16/18 cervical cancer vaccine, Cervarix. Adv Ther. 2009, 26: 983-998.CrossRefPubMed
24.
go back to reference Dunne EF, Datta SD, E Markowitz L: A review of prophylactic human papillomavirus vaccines: recommendations and monitoring in the US. Cancer. 2008, 113 (Suppl 10): 2995-3003.CrossRefPubMed Dunne EF, Datta SD, E Markowitz L: A review of prophylactic human papillomavirus vaccines: recommendations and monitoring in the US. Cancer. 2008, 113 (Suppl 10): 2995-3003.CrossRefPubMed
25.
go back to reference Einstein MH, Baron M, Levin MJ, Chatterjee A, Edwards RP, Zepp F, Carletti I, Dessy FJ, Trofa AF, Schuind A, Dubin G, HPV-010 Study Group: Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18–45 years. Hum Vaccin. 2009, 5: 705-719.CrossRefPubMed Einstein MH, Baron M, Levin MJ, Chatterjee A, Edwards RP, Zepp F, Carletti I, Dessy FJ, Trofa AF, Schuind A, Dubin G, HPV-010 Study Group: Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18–45 years. Hum Vaccin. 2009, 5: 705-719.CrossRefPubMed
26.
go back to reference Muñoz N, Manalastas R, Pitisuttithum P, Tresukosol D, Monsonego J, Ault K, Clavel C, Luna J, Myers E, Hood S, Bautista O, Bryan J, Taddeo FJ, Esser MT, Vuocolo S, Haupt RM, Barr E, Saah A: Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24–45 years: a randomised, double-blind trial. Lancet. 2009, 373: 1949-1957.CrossRefPubMed Muñoz N, Manalastas R, Pitisuttithum P, Tresukosol D, Monsonego J, Ault K, Clavel C, Luna J, Myers E, Hood S, Bautista O, Bryan J, Taddeo FJ, Esser MT, Vuocolo S, Haupt RM, Barr E, Saah A: Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24–45 years: a randomised, double-blind trial. Lancet. 2009, 373: 1949-1957.CrossRefPubMed
27.
go back to reference Paavonen J, Naud P, Salmerón J, Wheeler CM, Chow SN, Apter D, Kitchener H, Castellsague X, Teixeira JC, Skinner SR, Hedrick J, Jaisamrarn U, Limson G, Garland S, Szarewski A, Romanowski B, Aoki FY, Schwarz TF, Poppe WA, Bosch FX, Jenkins D, Hardt K, Zahaf T, Descamps D, Struyf F, Lehtinen M, Dubin G, HPV PATRICIA Study Group: Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a doubleblind, randomised study in young women. Lancet. 2009, 374: 301-314.CrossRefPubMed Paavonen J, Naud P, Salmerón J, Wheeler CM, Chow SN, Apter D, Kitchener H, Castellsague X, Teixeira JC, Skinner SR, Hedrick J, Jaisamrarn U, Limson G, Garland S, Szarewski A, Romanowski B, Aoki FY, Schwarz TF, Poppe WA, Bosch FX, Jenkins D, Hardt K, Zahaf T, Descamps D, Struyf F, Lehtinen M, Dubin G, HPV PATRICIA Study Group: Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a doubleblind, randomised study in young women. Lancet. 2009, 374: 301-314.CrossRefPubMed
28.
go back to reference Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, Perez G, Brown DR, Koutsky LA, Tay EH, García P, Ault KA, Garland SM, Leodolter S, Olsson SE, Tang GW, Ferris DG, Paavonen J, Lehtinen M, Steben M, Bosch FX, Dillner J, Joura EA, Majewski S, Muñoz N, Myers ER, Villa LL, Taddeo FJ, Roberts C, Tadesse A, Bryan J, et al: A pooled analysis of continued prophylactic prophylactic efficacy of quadrivalent human papillomavirus (types 6/11/16/18) vaccine against high grade cervical and external genital lesions. Cancer Prev Res. 2009, 2: 868-878.CrossRef Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, Perez G, Brown DR, Koutsky LA, Tay EH, García P, Ault KA, Garland SM, Leodolter S, Olsson SE, Tang GW, Ferris DG, Paavonen J, Lehtinen M, Steben M, Bosch FX, Dillner J, Joura EA, Majewski S, Muñoz N, Myers ER, Villa LL, Taddeo FJ, Roberts C, Tadesse A, Bryan J, et al: A pooled analysis of continued prophylactic prophylactic efficacy of quadrivalent human papillomavirus (types 6/11/16/18) vaccine against high grade cervical and external genital lesions. Cancer Prev Res. 2009, 2: 868-878.CrossRef
29.
go back to reference Grant LA, Dunne EF, Chesson H, Markowitz LE: Considerations for human papillomavirus (HPV) vaccination of mid-adult women in the United States. Vaccine. 2011, 29: 2365-2370.CrossRefPubMed Grant LA, Dunne EF, Chesson H, Markowitz LE: Considerations for human papillomavirus (HPV) vaccination of mid-adult women in the United States. Vaccine. 2011, 29: 2365-2370.CrossRefPubMed
30.
go back to reference Katki H, Wacholder S, Solomon D, Castle PE, Schiffman M: Risk estimation for the next generation of prevention programmes for cervical cancer. Lancet Oncol. 2009, 10: 1022-1023.CrossRefPubMedPubMedCentral Katki H, Wacholder S, Solomon D, Castle PE, Schiffman M: Risk estimation for the next generation of prevention programmes for cervical cancer. Lancet Oncol. 2009, 10: 1022-1023.CrossRefPubMedPubMedCentral
32.
go back to reference Human papillomaviruses. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, A Review of Human Carcinogens. 2011, Lion France, 255-313. Volume 100, Part B: Biological Agents Human papillomaviruses. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, A Review of Human Carcinogens. 2011, Lion France, 255-313. Volume 100, Part B: Biological Agents
33.
go back to reference Wright TC, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D: 2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests. Am J Obstet Gynecol. 2007, 197: 346-355.CrossRefPubMed Wright TC, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D: 2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests. Am J Obstet Gynecol. 2007, 197: 346-355.CrossRefPubMed
34.
go back to reference Kurman RJ, Ellenson LH, Ronnett BM: Precancerous lesions of the cervix. In Blaustein’s Pathology of the Female Genital Tract. Edited by: Springer Verlag New York. 2011, 6 Kurman RJ, Ellenson LH, Ronnett BM: Precancerous lesions of the cervix. In Blaustein’s Pathology of the Female Genital Tract. Edited by: Springer Verlag New York. 2011, 6
35.
go back to reference Puranen M, Saarikoski S, Syrjänen K, Syrjänen S: Polymerase chain reaction amplification of human papillomavirus DNA from archival, Papanicolaou-stained cervical smears. Acta Cytol. 1996, 40: 391-395.CrossRefPubMed Puranen M, Saarikoski S, Syrjänen K, Syrjänen S: Polymerase chain reaction amplification of human papillomavirus DNA from archival, Papanicolaou-stained cervical smears. Acta Cytol. 1996, 40: 391-395.CrossRefPubMed
36.
go back to reference Orlando G, Bianchi S, Mazza F, Fasolo M, Amendola A, Tanzi E: Concordance between paired cervical and urine samples in HPV-DNA detection and HPV genotyping. The Lancet conferences: HPV and cancer. nov 2010, P 19-Amsterdam 12–13 Orlando G, Bianchi S, Mazza F, Fasolo M, Amendola A, Tanzi E: Concordance between paired cervical and urine samples in HPV-DNA detection and HPV genotyping. The Lancet conferences: HPV and cancer. nov 2010, P 19-Amsterdam 12–13
37.
go back to reference Arias-Pulido H, Peyton CL, Torrez-Martínez N, Anderson DN, Wheeler CM: Human papillomavirus type 18 variant lineages in United States populations characterized by sequence analysis of LCR-E6, E2, and L1 regions. Virology. 2005, 338: 22-34.CrossRefPubMed Arias-Pulido H, Peyton CL, Torrez-Martínez N, Anderson DN, Wheeler CM: Human papillomavirus type 18 variant lineages in United States populations characterized by sequence analysis of LCR-E6, E2, and L1 regions. Virology. 2005, 338: 22-34.CrossRefPubMed
38.
go back to reference Tanzi E, Amendola A, Bianchi S, Fasolo MM, Beretta R, Pariani E, Zappa A, Frati E, Orlando G: Human papillomavirus genotypes and phylogenetic analysis of HPV-16 variants in HIV-1 infected subjects in Italy. Vaccine. 2009, 27 (Suppl1): 17-23.CrossRef Tanzi E, Amendola A, Bianchi S, Fasolo MM, Beretta R, Pariani E, Zappa A, Frati E, Orlando G: Human papillomavirus genotypes and phylogenetic analysis of HPV-16 variants in HIV-1 infected subjects in Italy. Vaccine. 2009, 27 (Suppl1): 17-23.CrossRef
39.
go back to reference Thompson JD, Gibson TJ, Plewniak F, Jeanmougin F, Higgins DG: The ClustalX windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools. Nucl Acids Res. 1997, 25: 4876-4882.CrossRefPubMedPubMedCentral Thompson JD, Gibson TJ, Plewniak F, Jeanmougin F, Higgins DG: The ClustalX windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools. Nucl Acids Res. 1997, 25: 4876-4882.CrossRefPubMedPubMedCentral
40.
go back to reference Hall TA: BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT. Nucl Acids Symp Ser. 1999, 41: 95-98. Hall TA: BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT. Nucl Acids Symp Ser. 1999, 41: 95-98.
41.
go back to reference Tamura K, Dudley J, Nei M, Kumar S: MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) software version 4.0. Mol Biol Evol. 2007, 24: 1596-1599.CrossRefPubMed Tamura K, Dudley J, Nei M, Kumar S: MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) software version 4.0. Mol Biol Evol. 2007, 24: 1596-1599.CrossRefPubMed
42.
go back to reference Felsenstein J: Confidence limits on phylogenies: An approach using the bootstrap. Evolution. 1985, 39: 783-791.CrossRef Felsenstein J: Confidence limits on phylogenies: An approach using the bootstrap. Evolution. 1985, 39: 783-791.CrossRef
43.
go back to reference Yamada T, Wheeler CM, Halpern AL, Stewart AC, Hildesheim A, Jenison SA: Human papillomavirus type 16 variant lineages in United States populations characterized by nucleotide sequence analysis of the E6, L2, and L1 coding segments. J Virol. 1995, 69: 7743-7753.PubMedPubMedCentral Yamada T, Wheeler CM, Halpern AL, Stewart AC, Hildesheim A, Jenison SA: Human papillomavirus type 16 variant lineages in United States populations characterized by nucleotide sequence analysis of the E6, L2, and L1 coding segments. J Virol. 1995, 69: 7743-7753.PubMedPubMedCentral
44.
go back to reference Yamada T, Manos MM, Peto J, Greer CE, Munoz N, Bosch FX, Wheeler CM: Human papillomavirus type 16 sequence variation in cervical cancers: a worldwide perspective. J Virol. 1997, 71: 2463-2472.PubMedPubMedCentral Yamada T, Manos MM, Peto J, Greer CE, Munoz N, Bosch FX, Wheeler CM: Human papillomavirus type 16 sequence variation in cervical cancers: a worldwide perspective. J Virol. 1997, 71: 2463-2472.PubMedPubMedCentral
45.
go back to reference Frati E, Bianchi S, Colzani D, Zappa A, Orlando G, Tanzi E: Genetic variability in the major capsid L1 protein of Human Papillomavirus type 16 (HPV-16) and 18 (HPV-18). Infect Genet Evol. 2011, 11: 2119-2124.CrossRefPubMed Frati E, Bianchi S, Colzani D, Zappa A, Orlando G, Tanzi E: Genetic variability in the major capsid L1 protein of Human Papillomavirus type 16 (HPV-16) and 18 (HPV-18). Infect Genet Evol. 2011, 11: 2119-2124.CrossRefPubMed
46.
go back to reference Kosakovsky Pond SL, Frost SDW: Datamonkey: rapid detection of selective pressure on individual sites of codon alignaments. Bioinf. 2005, 21: 2531-2533.CrossRef Kosakovsky Pond SL, Frost SDW: Datamonkey: rapid detection of selective pressure on individual sites of codon alignaments. Bioinf. 2005, 21: 2531-2533.CrossRef
Metadata
Title
Rationale and design of a multicenter prospective cohort study for the eVALuation and monitoring of HPV infections and relATEd cervical diseases in high-risk women (VALHIDATE study)
Authors
Giovanna Orlando
Elisabetta Tanzi
Liliane Chatenoud
Maria Gramegna
Giuliano Rizzardini
VALHIDATE Study Group
Publication date
01-12-2012
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2012
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-12-204

Other articles of this Issue 1/2012

BMC Cancer 1/2012 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine